Luana Pillon, MD
Nephrology · Las Vegas, NVNPI 1679567309
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,500 of the $8,587 with a category attached, or 64.1%. 23 manufacturers reported payments, led by Amgen at 38.6% of the total. 2025 is the largest year on record at $2,471, 4.4 times the $557 reported in 2019. Among nephrology clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 149 payments — averaging $57.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Travere Therapeutics, Inc.$2K
- AstraZeneca$658
- GSK$413
- Novo Nordisk$388
- Regeneron Healthcare Solutions, Inc.$317
- plus $2K from 17 others
What the payments were for
- Consulting fees$971%
- Speaking & faculty fees$1,57518%
- Travel & lodging$86910%
- Food & beverage$5,50064%
- Education$5456%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 47 | $3,310 |
| Travere Therapeutics, Inc. | 19 | $1,656 |
| AstraZeneca(2 entities) | 10 | $658 |
| GSK | 11 | $413 |
| Novo Nordisk | 4 | $388 |
| Regeneron Healthcare Solutions, Inc. | 3 | $317 |
| ANI Pharmaceuticals, Inc. | 15 | $285 |
| Novartis | 6 | $207 |
| Bayer | 9 | $193 |
| Aurinia Pharma U.S., Inc. | 3 | $162 |
| E.r. Squibb & Sons, L.L.C. | 2 | $146 |
| Otsuka America Pharmaceutical, Inc. | 1 | $145 |
| Abbott | 2 | $140 |
| Genentech, Inc. | 1 | $129 |
| Viiv Healthcare Company | 1 | $125 |
| Vifor Pharma, Inc. | 6 | $114 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $53 |
| Akebia Therapeutics Inc | 2 | $49 |
| Calliditas Therapeutics US Inc. | 1 | $29 |
| Genentech USA, Inc. | 1 | $21 |
| OPKO Pharmaceuticals, LLC | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
| Pharmacosmos Therapeutics Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,587 in reported general payments places this provider in the 90th percentile of 125 nephrology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 182 | $154,613 |
| FarxigaDapagliflozin Propanediol | 104 | $84,221 |
| OzempicSemaglutide | 27 | $38,339 |
| VeltassaPatiromer Calcium Sorbitex | 31 | $38,001 |
| JardianceEmpagliflozin | 50 | $28,460 |
| LokelmaSodium Zirconium Cyclosilicate | 17 | $25,167 |
| MounjaroTirzepatide | 17 | $22,915 |
| RybelsusSemaglutide | 11 | $10,437 |
| DapagliflozinDapagliflozin Propanediol | 12 | $5,875 |
| Fenofibrate | 12 | $3,016 |
| Potassium Chloride | 37 | $1,132 |
| Nifedipine ErNifedipine | 28 | $956 |
| Losartan Potassium | 107 | $917 |
| Olmesartan Medoxomil | 65 | $773 |
| Telmisartan | 20 | $694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerKerendia | $193 | $154,613182 claims |
| AstraZenecaFarxiga, Lokelma | $658 | $109,387121 claims |
| Novo NordiskOzempic, Rybelsus | $388 | $48,77638 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $285 | $38020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 125 nephrology providers in Nevada.
Other nephrology in Las Vegas
- Samuel KantorLas Vegas$319K
- Richard CottieroLas Vegas$220K
- Mark VishnepolskyLas Vegas$68K
- Baishali NairLas Vegas$12K
- Gene OngLas Vegas$11K
- Jeffrey RyuLas Vegas$9K
- Lawrence LehrnerLas Vegas$8K
- Hassan OsmanLas Vegas$8K
- Marwan TakieddineLas Vegas$8K
- Prateek SangheraLas Vegas$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.